It was demonstrated to be an LXRα antagonist and displays efficacy in treating NAFLD as it significantly decreased TC accumulation and induced steatosis at 20 μM through modulation of LXRα, transcription factor SREBP-1c, and a battery of downstream target genes (Lin et al., 2018). Here, NR1H3 is linked to metabolic dysfunction-associated steatotic liver disease.